Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongshuan Jiuxin Pian is a Traditional Chinese Medicine (TCM) formulation developed by Jinhua Enterprise (Group) Co., Ltd. for the treatment of cardiovascular conditions, specifically chronic stable angina pectoris. It is indicated for patients exhibiting the Qi stagnation and blood stasis pattern according to TCM diagnostics. The drug is formulated as a tablet and is intended to improve exercise tolerance and alleviate symptoms associated with coronary artery disease. It has been evaluated in Phase 3 clinical trials in China (e.g., CTR20140830) to assess its efficacy and safety compared to placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongshuan Jiuxin Pian.